GLP-1 Coverage in Medicaid: What Care Coordinators Need to Know in 2026

GLP-1 receptor agonists have generated more coverage policy movement in the past two years than almost any other drug class. The clinical indications have expanded — from type 2 diabetes to obesity management, cardiovascular risk reduction, metabolic-associated steatohepatitis (MASH), and obstructive sleep apnea. The coverage policies have not kept pace with the approvals, and they vary significantly by state, by indication, and in some cases by which MCO the patient is enrolled in.

For care coordinators managing Medicaid populations, GLP-1 coverage is one of the most frequently misunderstood areas of formulary navigation in 2026. Here is what the current coverage landscape looks like and what to verify before these drugs are prescribed.

The GLP-1 Class in Current Use

The GLP-1 receptor agonists and dual agonists in common clinical use include semaglutide (Ozempic for diabetes, Wegovy for obesity), tirzepatide (Mounjaro for diabetes, Zepbound for obesity), dulaglutide (Trulicity), and liraglutide (Victoza for diabetes, Saxenda for obesity). The brand name and the indication are not interchangeable from a coverage perspective. Ozempic and Wegovy contain the same active ingredient at different doses — but they have different NDCs, different formulary positions, and potentially different PA criteria under the same plan.

This distinction matters enormously for Medicaid coverage. A state that covers semaglutide for type 2 diabetes (Ozempic) may not cover it for obesity management (Wegovy) under the same formulary. The clinical decision to prescribe semaglutide is one question; the coverage question must be asked separately for each indication and each specific product.

Michigan: What Changed in January 2026

Michigan's Medicaid program added prior authorization pathways for GLP-1 obesity agents effective January 1, 2026 under the 2025–2026 State Prescribed Drug List. This includes coverage for semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) for obesity management — an indication that was not covered through Michigan Medicaid in prior plan years.

The PA criteria for the obesity indication require documented BMI criteria, prior trials of behavioral or dietary interventions, absence of contraindications, and prescriber documentation of medical necessity. The specific criteria apply to all Michigan Medicaid MCOs; this is a state-level PA requirement, not plan-specific.

The DPP-4 + GLP-1 Concurrent Use Restriction

One of the more operationally significant coverage changes in Michigan took effect February 2025: concurrent use of a DPP-4 inhibitor and a GLP-1 receptor agonist is no longer covered under Michigan Medicaid. If a patient is actively prescribed a DPP-4 inhibitor (sitagliptin, saxagliptin, alogliptin, linagliptin), Michigan Medicaid will not cover a GLP-1 agent on the same claim without documented discontinuation of the DPP-4 agent.

This reflects both clinical guidance — the combination provides minimal additional glycemic benefit over either agent alone — and formulary stewardship. The practical implication is that care coordinators need to review a patient's current medication list for DPP-4 agents before initiating a GLP-1 PA request. Submitting without this check will result in a denial that requires additional documentation and a re-submission.

Coverage by Indication: A Simplified Guide

Drug / Brand	Indication	Michigan Medicaid (2025–2026)	Notes
Semaglutide (Ozempic)	Type 2 Diabetes	Covered with PA	Step therapy may apply; check for metformin/sulfonylurea requirements
Semaglutide (Wegovy)	Obesity / Weight Management	Covered with PA (eff. Jan 2026)	BMI criteria required; separate from Ozempic coverage
Tirzepatide (Mounjaro)	Type 2 Diabetes	Covered with PA	Dual GLP-1/GIP agonist; check concurrent DPP-4 restriction
Tirzepatide (Zepbound)	Obesity / OSA	Covered with PA (eff. Jan 2026)	OSA indication requires separate documentation pathway
Liraglutide (Victoza)	Type 2 Diabetes / CV Risk	Covered with PA	CV risk reduction indication; document ASCVD history
Liraglutide (Saxenda)	Obesity	Covered with PA (eff. Jan 2026)	Separate NDA from Victoza; requires obesity documentation
Dulaglutide (Trulicity)	Type 2 Diabetes / CV Risk	Covered with PA	Once-weekly injection; CV risk indication available

Cardiovascular Risk Reduction and MASH: Separate PA Pathways

FDA approvals for GLP-1 agents have expanded beyond diabetes and obesity. Semaglutide received approval for cardiovascular risk reduction in patients with established cardiovascular disease, independent of diabetes status. Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, received FDA approval for MASH in 2024 — a distinct drug class but often discussed alongside GLP-1 agents in the context of metabolic disease management. Tirzepatide received FDA approval for obstructive sleep apnea in 2024.

Each of these indications has a distinct PA pathway in states that cover them. The cardiovascular risk reduction indication for liraglutide and semaglutide requires documentation of established ASCVD, which is different from the diabetes PA pathway. Submitting a diabetes PA for a patient whose primary indication is cardiovascular risk reduction — or vice versa — will produce a denial that requires the documentation to be resubmitted with indication-specific criteria.

What to Check Before Submitting a GLP-1 PA

For any GLP-1 PA for a Michigan Medicaid patient, the minimum verification steps are: confirm the correct product and NDC for the intended indication; confirm the patient is not currently on a DPP-4 inhibitor; confirm the patient meets the BMI or diagnosis criteria for the indication; confirm which MCO the patient is enrolled in and whether plan-specific criteria apply on top of the state PDL requirements; and confirm the current formulary tier and any quantity limit that applies.

GLP-1 agents are among the highest-cost drugs in the Medicaid formulary. The PA scrutiny is high, the denial rate for incomplete submissions is high, and the re-submission burden is significant. Getting the documentation right before the first submission is substantially more efficient than navigating the appeals process after a denial.